Briefing
Postoperative ctDNA could potentially spare patients from unnecessary adjuvant therapy in HPV-negative head and neck squamous cell carcinoma: a meta-analysis
This meta-analysis of 8 studies (n=325) found that detectable postoperative ctDNA in HPV-negative HNSCC was associated with shorter recurrence-free survival (pooled HR 10.07, 95% CI 5.64-17.99) and overall survival (HR 8.98, 95% CI 2.93-27.58). Sensitivity analyses brought the recurrence-free survival HR down to a range of 2.22-2.43. The authors conclude that postoperative ctDNA remains investigational in this setting because of small samples, mixed methods, and unstable estimates.
- Design: Evidence level 3
- Assay: Not named in the abstract
Frontiers in OncologyPubMed 42964065DOI 10.3389/fonc.2026.1902328